Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-08-21

FDA Approved: DEXMETHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)

View source ↗

Summary

The FDA approved Teva's supplemental application for a generic dexmethylphenidate hydrochloride product, expanding ADHD treatment options.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • DEXMETHYLPHENIDATE HYDROCHLORIDE (dexmethylphenidate hydrochloride)

Snippet

SUPPL AP for DEXMETHYLPHENIDATE HYDROCHLORIDE (DEXMETHYLPHENIDATE HYDROCHLORIDE)